CoChat
Sign Up
Cited by 66

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis

Pelliccia, Francesco, Pasceri, Vincenzo, Limongelli, Giuseppe, Autore, Camillo, Basso, Cristina, Corrado, Domenico, Imazio, Massimo, Rapezzi, Claudio, Sinagra, Gianfranco, Mercuro, Giuseppe·2017·International Journal of Cardiology
DOI 10.1016/j.ijcard.2017.06.071
Open this paper in CoChat — free account

Abstract

Background Prognosis of hypertrophic cardiomyopathy (HCM) is particularly heterogeneous. Patients with nonobstructive HCM (NOCM) are thought to be at relatively low-risk as compared with obstructive HCM (HOCM) with no need of major treatment options. However, available evidence of NOCM comes mainly from tertiary centers where a referral bias is likely to occur. Aim of this study was to perform a systematic review and meta-analysis of the published literature on hypertrophic cardiomyopathy (HCM) in order to outline differences in presenting features and long-term outcome between NOCM and HOCM. Methods MEDLINE/Pubmed, EMBASE and Cochrane databases up to December 31, 2016, and reviewed cited references to identify relevant studies were used. The primary endpoints were HCM-related overall mortality rate and yearly rate of cardiac death. Other endpoints were incidences of sudden and congestive heart failure deaths. Results A total of 20 studies entered the meta-analysis on the long-term outcome of NOCM vs HOCM. They included a total of 7731 patients, 5058 patients with NOCM (65%) and 2673 patients with HOCM (35%). During the follow-up, annual mortality related to HCM averaged 1.55% in NOCM and 1.77% in HOCM (Relative Risk: 0.89, 95% confidence intervals: 0.68 to 1.17, p=0.40). Overall, 5 studies reported significantly higher mortality for HOCM, 3 higher mortality for NOCM, and 12 no significant differences. Conclusion This large study-level meta-analysis shows that long-term morta…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijcard.2017.06.071

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 48

  1. Elliott, 2016, Hypertrophic cardiomyopathy: job done or work in progress?, J. Am. Coll. Cardiol., 67, 1410, 10.1016/j.jacc.2016.02.009 · DOI
  2. Maron, 2017, Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored … until now, Am. J. Med., 130, 119, 10.1016/j.amjmed.2016.09.015 · DOI
  3. Maron, 2016, Hypertrophic cardiomyopathy in children, adolescents and young adults associated with low cardiovascular mortality with contemporary management strategies, Circulation, 133, 63, 10.1161/CIRCULATIONAHA.115.017633 · DOI
  4. Maron, 2015, Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies, J. Am. Coll. Cardiol., 65, 1915, 10.1016/j.jacc.2015.02.061 · DOI · Paper page
  5. Maron, 2006, Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, 114, 2232, 10.1161/CIRCULATIONAHA.106.644682 · DOI
  6. Maron, 2009, The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy, J. Am. Coll. Cardiol., 54, 191, 10.1016/j.jacc.2008.11.069 · DOI
  7. O'Mahony, 2013, Sudden cardiac death in hypertrophic cardiomyopathy, Circ. Arrhythm. Electrophysiol., 6, 443, 10.1161/CIRCEP.111.962043 · DOI
  8. Kim, 2015, Differences in apical and non-apical types of hypertrophic cardiomyopathy: a prospective analysis of clinical, echocardiographic, and cardiac magnetic resonance findings and outcome from 350 patients, Eur. Heart J. Cardiovasc. Imaging
  9. Hebl, 2016, The natural history of nonobstructive hypertrophic cardiomyopathy, Mayo Clin. Proc., 91, 279, 10.1016/j.mayocp.2016.01.002 · DOI
  10. Sen-Chowdhry, 2016, Update on hypertrophic cardiomyopathy and a guide to the guidelines, Nat. Rev. Cardiol., 13, 651, 10.1038/nrcardio.2016.140 · DOI
  11. Rowin, 2014, Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant, Circ. Heart Fail., 7, 967, 10.1161/CIRCHEARTFAILURE.114.001435 · DOI
  12. Jan, 2016, Apical hypertrophic cardiomyopathy: present status, Int. J. Cardiol., 222, 745, 10.1016/j.ijcard.2016.07.154 · DOI
  13. Gersh, 2011, J. Am. Coll. Cardiol., 58, e212, 10.1016/j.jacc.2011.06.011 · DOI · Paper page
  14. Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology, Eur. Heart J., 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  15. Slim, 2003, Methodological index for non-randomized studies (minors): development and validation of a new instrument, ANZ J. Surg., 73, 712, 10.1046/j.1445-2197.2003.02748.x · DOI · Paper page
  16. DerSimonian, 1986, Meta-analysis in clinical trials, Control. Clin. Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  17. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  18. Romeo, 1990, Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant?, Eur. Heart J., 11, 233, 10.1093/oxfordjournals.eurheartj.a059689 · DOI
  19. Fananapazir, 1992, Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings, Circulation, 86, 730, 10.1161/01.CIR.86.3.730 · DOI
  20. Cecchi, 1995, Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population, J. Am. Coll. Cardiol., 26, 1529, 10.1016/0735-1097(95)00353-3 · DOI
  21. Maki, 1998, Predictors of sudden cardiac death in hypertrophic cardiomyopathy, Am. J. Cardiol., 82, 774, 10.1016/S0002-9149(98)00455-X · DOI
  22. Kyriakidis, 1998, Hypertrophic cardiomyopathy in Greece: clinical course and outcome, Chest, 114, 1091, 10.1378/chest.114.4.1091 · DOI
  23. Spirito, 2000, Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy, N. Engl. J. Med., 342, 1778, 10.1056/NEJM200006153422403 · DOI
  24. Kofflard, 2003, Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration, J. Am. Coll. Cardiol., 41, 987, 10.1016/S0735-1097(02)03004-8 · DOI
  25. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N. Engl. J. Med., 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  26. Arteaga, 2005, Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil, Am. Heart J., 149, 1099, 10.1016/j.ahj.2004.09.049 · DOI
  27. Autore, 2005, The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms, J. Am. Coll. Cardiol., 45, 1076, 10.1016/j.jacc.2004.12.067 · DOI
  28. Elliott, 2006, Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy, Eur. Heart J., 27, 1933, 10.1093/eurheartj/ehl041 · DOI
  29. Melacini, 2007, Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy, Heart, 93, 708, 10.1136/hrt.2006.099416 · DOI
  30. Efthimiadis, 2013, Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction, Circ. J., 77, 2366, 10.1253/circj.CJ-12-1561 · DOI
  31. Maron, 2013, Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age, Circulation, 127, 585, 10.1161/CIRCULATIONAHA.112.136085 · DOI · Paper page
  32. Desai, 2014, Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes, JACC Cardiovasc. Imaging, 7, 26, 10.1016/j.jcmg.2013.08.010 · DOI
  33. Vriesendorp, 2014, Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy, JACC Heart Fail., 2, 630, 10.1016/j.jchf.2014.06.012 · DOI
  34. Spirito, 2014, Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors, Am. J. Cardiol., 113, 1550, 10.1016/j.amjcard.2014.01.435 · DOI
  35. Espinola-Zavaleta, 2015, Survival and clinical behavior of hypertrophic cardiomyopathy in a Latin American cohort in contrast to cohorts from the developed world, J. Cardiovasc. Ultrason., 23, 20, 10.4250/jcu.2015.23.1.20 · DOI
  36. Pozios, 2015, Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy, Am. J. Cardiol., 116, 938, 10.1016/j.amjcard.2015.06.018 · DOI
  37. Maron, 2016, Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy, J. Am. Coll. Cardiol., 67, 1399, 10.1016/j.jacc.2016.01.023 · DOI
  38. Webb, 1990, Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates, J. Am. Coll. Cardiol., 15, 83, 10.1016/0735-1097(90)90180-W · DOI
  39. Aron, 1991, Prognosis of nonobstructive hypertrophic cardiomyopathy, Am. J. Cardiol., 67, 215, 10.1016/0002-9149(91)90450-Y · DOI
  40. Moro, 1995, Long-term evaluation of patients with apical hypertrophic cardiomyopathy. Correlation between quantitative echocardiographic assessment of apical hypertrophy and clinical-electrocardiographic findings, Eur. Heart J., 16, 210, 10.1093/oxfordjournals.eurheartj.a060887 · DOI
  41. Abinader, 2002, Novel insights into the natural history of apical hypertrophic cardiomyopathy during long-term follow-up, Isr. Med. Assoc. J., 4, 166
  42. Eriksson, 2002, Long-term outcome in patients with apical hypertrophic cardiomyopathy, J. Am. Coll. Cardiol., 39, 638, 10.1016/S0735-1097(01)01778-8 · DOI
  43. Ho, 2004, Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy, Am. J. Med., 116, 19, 10.1016/j.amjmed.2003.09.020 · DOI
  44. Lee, 2006, Clinical features and outcome of patients with apical hypertrophic cardiomyopathy in Taiwan, Cardiology, 106, 29, 10.1159/000092590 · DOI
  45. Chen, 2011, Apical hypertrophic cardiomyopathy: correlations between echocardiographic parameters, angiographic left ventricular morphology, and clinical outcomes, Clin. Cardiol., 34, 233, 10.1002/clc.20874 · DOI
  46. Moon, 2011, Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy, Am. J. Cardiol., 108, 1614, 10.1016/j.amjcard.2011.07.024 · DOI
  47. Klarich, 2013, Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy, Am. J. Cardiol., 111, 1784, 10.1016/j.amjcard.2013.02.040 · DOI
  48. Cai, 2014, Comparison of the prevalence, clinical features, and long-term outcomes of midventricular hypertrophy vs apical phenotype in patients with hypertrophic cardiomyopathy, Can. J. Cardiol., 30, 441, 10.1016/j.cjca.2013.10.005 · DOI

Cited by

Sorted by citations

Metadata

Authors
Pelliccia, F., Pasceri, V., Limongelli, G., Autore, C., Basso, C., Corrado, D., Imazio, M., Rapezzi, C., Sinagra, G., & Mercuro, G.
Venue
International Journal of Cardiology
Publisher
Elsevier BV
Published
2017-09
Volume
243
Pages
379-384
ISSN
0167-5273
DOI
10.1016/j.ijcard.2017.06.071
Cited by
66
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review